Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D costs rise...again

Executive Summary

Medicare spending estimates for Part D increased by $6.4 bil. to a total of $855.7 bil. over 2006 to 2015 due to a new inflation rate forecast, the Congressional Budget Office says. The 10-year projection period CBO uses to predict spending has changed since the MMA was enacted. It now spans 2006 to 2015 rather than 2004 to 2013 and therefore includes two additional years of prescription drug benefits. CBO had originally predicted spending for Part D from 2004 to 2013 would be $552 bil., then raised the estimate for the same time period to $593 bil. in March (1"The Pink Sheet" March 14, 2005, In Brief). The net cost includes offsetting funds for Part D premiums but does not incorporate expected savings to Medicaid and other federal programs. The most recent estimate is already outdated since CBO completed its summer update before the Centers for Medicare & Medicaid Services announced the lower than expected base premium levels for Part D (2"The Pink Sheet" Aug. 15, 2005, p. 19)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel